Company news
Terns Pharmaceuticals, Inc. news in 2025
Terns Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 10, 2025
Terns Announces Proposed Public Offering
December 8, 2025
Terns Announces Pricing of Upsized $650 Million Public Offering
December 8, 2025
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
December 7, 2025
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
November 13, 2025
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 9, 2025
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
November 2, 2025
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
October 22, 2025
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
October 20, 2025
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
August 20, 2025
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 4, 2025
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
June 22, 2025
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
May 28, 2025
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
May 13, 2025
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 7, 2025
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
April 29, 2025
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
April 1, 2025
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
March 19, 2025
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
February 25, 2025
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
February 24, 2025
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
February 23, 2025
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
February 19, 2025
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 4, 2025
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
February 2, 2025
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025